Business Wire

GENECAST Launches BRAF Mutation Test Kits with the Highest Detection Sensitivity 0.0001%

Share

GENECAST, cancer diagnostics company through liquid biopsy, today announced the launch of ADPSTM BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity for Research Use Only (RUO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005007/en/

GENECAST, cancer diagnostics company through liquid biopsy, launched ADPSTM BRAF, EGFR, JAK2 mutatio ...

GENECAST, cancer diagnostics company through liquid biopsy, launched ADPSTM BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity for Research Use Only (RUO). ADPS(TM) BRAF Mutation Test Kit (RUO) (Photo: Business Wire)

Especially ADPSTM BRAF mutation test kit has 0.0001% detection sensitivity which is 100 times higher than any other products, as well as EGFR and JAK2 mutation kits have the high detection sensitivity of 0.01%.

Detection sensitivity is the most important indicator of determining the accuracy of liquid biopsy. According to Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Dev 2017; 42:14-21, high detection sensitivity of 0.01% or less is important for early diagnose cancer using liquid biopsy.

ADPSTM BRAF mutation test kit can diagnose 4 BRAF mutations that are mainly found in thyroid cancer and melanoma with 0.0001% of detection sensitivity -meaning 3/3,000,000 mutation genes can be detected. It is 100 times better than ddPCR which previously had the highest detection sensitivity. Since ADPS technology is based on qPCR, it can reduce the expense and shorten clinical test time.

GENECAST is speeding up certification and approval procedures so that the kits can be used in the clinical fields. ADPSTM EGFR Mutation test kit which diagnoses EGFR- the most common cancer mutation in NSCLC, is in a process of FDA PMA. This is the world’s second trial as liquid biopsy cancer diagnostic kit. GENECAST plans to get FDA PMA approval by the second half of 2021. Also will prepare for CE-IVD after getting ISO 13485:2016 certification by this September.

“ADPS Oncology kits will show the possibility of precision medicine in the 1st and 2nd stage cancer patients,” said Ph.D. ByungChul Lee, CTO of GENECAST. “Yet, not becoming complacent, we will actualize early cancer diagnosis through liquid biopsy by continuously developing diverse cancer kits and new technologies.”

GENECAST will launch KRAS, NRAS, PIK3CA, pTERT, IDH1, IDH2 mutation test kits(RUO) by the end of 2019, and complete certification of CE-IVD for 9 Oncology kits by the first half of 2020.

About GENECAST

GENECAST is a genetic testing start-up with liquid biopsy, specialized in monitoring cancer with original Allele-Discriminating Priming System (ADPS) that boasts an unprecedented sensitivity of 0.0001%. GENECAST’s mission is to make cancer as commonly curable disease by straightly face cancer with the highest detection sensitivity. ADPSTM EGFR mutation test kit is in the process of approving FDA PMA Class3 and aims to get approval by 2021. Besides ctDNA diagnostic technology, researchers are continuously developing new diagnostic technologies to fulfill the mission.

Contact information

GENECAST
Communication team
+82-2-2157-3150
Soobin Shin
comm@igenecast.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Arch Re to Acquire Global Credit & Surety Renewal Rights From Aspen Re21.11.2019 15:51:00 CETPress release

Arch Reinsurance (Arch Re), a wholly owned subsidiary of Arch Capital Group Ltd. (ACGL), and Aspen Reinsurance (Aspen Re), the reinsurance business segment of Aspen Insurance Holdings Limited (Aspen), jointly announced that Arch Re has entered into a renewal rights agreement with Aspen Re on its global credit and surety reinsurance business after Aspen Re’s decision to exit the line. In addition to the renewal rights on the portfolio, the parties have agreed to initiate additional discussions about the potential novation of the existing book in the coming months. Arch has extended employment offers to all of Aspen Re’s Zurich-based credit and surety employees to join Arch Re’s existing credit and surety team based in Zurich. “This is a unique opportunity for us to not only augment and diversify our credit and surety portfolio through the acquisition of Aspen Re’s renewal rights, but to also add talented employees to our team,” said Michael Hammer, President and CEO of Arch Re Europe. “

Daisy Wins AI Company of the Year at the Canadian FinTech & AI Awards21.11.2019 15:50:00 CETPress release

Daisy Intelligence was named AI Company of the Year at the prestigious Canadian FinTech & AI Awards. Daisy provides AI-powered solutions for the insurance and retail industries that deliver dramatically improved business results. “With Canada regarded as one of the global leaders in artificial intelligence, this award is a major accomplishment for Daisy,” said Gary Saarenvirta, founder and CEO of Daisy. “It reflects the growing recognition of our unique technology, and it is a step towards our vision of becoming the world’s largest and most respected AI company.” The Canadian FinTech & AI Awards recognize and celebrate Canadian innovation in financial technology and artificial intelligence. The awards were presented at the 5th Annual Canadian FinTech & AI Awards gala hosted by the Digital Finance Institute, a think tank that covers the nexus between FinTech, financial innovation, AI, financial regulation, and financial inclusion. “Daisy has established itself as one of the very few com

New CloudBlue Connect Delivers Omni-Product Platform that Unifies Multiple Channels21.11.2019 15:12:00 CETPress release

CloudBlue, an Ingram Micro business, today announced the global launch of CloudBlue ConnectTM, an omni-product platform aimed at helping vendors and service providers expand their reach and decrease time to market with minimal overhead costs. The CloudBlue Connect platform is capable of helping a company use only one system to manage its go-to-market channels – direct and indirect – supporting both traditional and recurring digital products and services. Furthermore, the platform automates many of the time-intensive tasks of managing a go-to-market channel, including contract management, maintaining product information, fulfillment, usage management and subscription services. “Vendors and service providers have long been struggling to manage multiple integrations for their partnership and channel programs and have been forced to invest a huge amount of resources in development and maintenance,” said Tarik Faouzi, vice president of CloudBlue. “CloudBlue Connect alleviates these issues,

Speech Processing Solutions: Philips Named One of the Top 3 Dictation & Transcription Services by Canadian Lawyers21.11.2019 14:58:00 CETPress release

Philips Dictation, by Speech Processing Solutions, is the market leader in professional dictation and has been named a preferred supplier of dictation and transcription services by lawyers and legal professionals in the fifth annual Canadian Lawyer Readers’ Choice Awards . These awards recognize legal products and service providers that rise above the competition. “We are honored that Philips has been recognized as one of the leading suppliers in speech-to-text solutions. We create our products with the goal of simplifying workflow and increasing productivity, and we are happy to have that reflected by professionals in the legal industry” says Dr. Thomas Brauner, CEO of Speech Processing Solutions. The professional Philips speech-to-text portfolio offers a variety of choices from future-proof cloud dictation to on-premise enterprise software. Combined with reliable, specialized dictation devices and the extension to smartphone dictation, legal professionals can leverage customizable so

CSC Releases Inaugural Securitization Industry Pulse Report21.11.2019 14:00:00 CETPress release

CSC, the world’s leading provider of business, legal, tax, and digital brand services, today announced the release of its inaugural securitization industry report, in conjunction with GlobalCapital, a top news, opinion, and data service dedicated to international capital markets. “Our research study is unique in that it provides a comprehensive view of the securitization industry across regions and asset classes rather than being asset or region-specific,” says John Hebert, senior vice president of CSC’s Global Financial Markets business. “Our report aims to define key issues facing the industry, understand how market participants are responding, and provide insights into the drivers and underlying forces impacting market trends.” The survey includes the opinions of the industry’s most prominent players—more than 150 issuers, arrangers, investors, and service providers—across North America, Europe, and Asia. The report arms stakeholders with expert predictions into the asset classes th

Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite21.11.2019 13:30:00 CETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced two new additions to the company’s leadership team. Charles Calderaro will join Kite as Global Head of Technical Operations, and Ken Takeshita, MD will join as Global Head of Clinical Development. Both Mr. Calderaro and Dr. Takeshita will report directly to Christi Shaw, Chief Executive Officer of Kite. “Innovation in manufacturing and scientific advancement are dually critical to the delivery and continued progress of cell therapy,” said Ms. Shaw. “We are pleased to welcome Charles and Ken, whose deep and diverse experience will bolster Kite’s leadership in cell therapy and ensure that we are best positioned to meet the needs of patients now and well into the future.” Mr. Calderaro will be responsible for leading all aspects of Kite’s technical operations, including process development, manufacturing, supply chain management, quality assurance and end-to-end optimization for the company’s commercial and pipeline products, effectiv